ClinicalTrials.gg
CompletedNCT05452304Updated Dec 3, 2025

AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease

A Phase 1 interventional study of AZD7798 and Placebo in Healthy Subjects and Crohns Disease, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Crohn Disease by AstraZeneca — none open to participants now, 2 under way, none of them phase 3. Crohn Disease · AstraZeneca.

Enrollment
4th of 13
112 · median 48
Started
2022
the only one that year
Phase 1
5 of 13
none open now
Registered
9th of 13
by date

Among the 13 studies in Crohn Disease by AstraZeneca, this one is the 4th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 1, and was the 9th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 13 studies in Crohn Disease by AstraZeneca is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Crohn Disease by AstraZeneca as a file.
02

Study summary

This study will assess the safety, tolerability, immunogenicity, and pharmacokinetics (PK), and explore the pharmacodynamics (PD) following single ascending dose administration and repeat dose administration in healthy subjects and patients with Crohn's disease.

Read the detailed description

This is a Phase I, randomised, double-blind, placebo controlled study in healthy male and female subjects as well as patients with Crohn's disease performed at a single study centre.

This study is comprised of 3 parts: Part 1 (sub-parts 1a and 1b), Part 2, and Part 3 (sub-Parts 3a and 3b).

  • Part 1a: This is a First-In-Human (FIH), single ascending dose (SAD) sequential group study. Up to 7 dose levels of AZD7798 are planned to be investigated. Depending on the findings, an additional dose may be added. Up to 80 healthy subjects are planned to be included. Eight subjects will participate in each single dose cohort. Within each cohort, 6 subjects will be randomised to receive AZD7798, and 2 subjects will be randomised to receive placebo. Each subject will be enrolled up to 113 days (approximately 16 weeks).
  • Part 1b: Up to 8 subjects will be randomised to receive a planned dose of AZD7798 (up to 6 subjects) or placebo (up to 2 subjects) on Day 1 and Day 15. This cohort is planned to start after completion of the single dose level cohort in Part 1a. Each subject will be enrolled up to 149 days (approximately 21 weeks).
  • Part 2: Up to 8 patients will be randomised (2:1:1) into 1 of 3 strata and receive:

    • Stratum 1: AZD7798 on Day 1 and Day 15 (up to 4 patients).
    • Stratum 2: Placebo on Day 1 and AZD7798 on Day 15 (up to 2 patients).
  • Stratum 3: AZD7798 on Day 1 and placebo on Day 15 (up to 2 patients). Each subject will be enrolled up to 149 days (approximately 21 weeks).
  • Part 3: Subjects will be randomised to AZD7798 or placebo in a ratio of 3:1 (up to 6 subjects will receive AZD7798 and up to 2 subjects will receive placebo).
03

Conditions studied

  • Healthy Subjects
  • Crohns Disease

Browse trials for

Keywords

  • AZD7798
  • Single ascending dose
  • Repeat dose
  • Sentinel dosing
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Study Parts:

  • Provision of signed and dated, written prior to any study specific procedures.
  • Subjects must have suitable veins for cannulation or repeated venepuncture.
  • Males who are sexually active with a female partner of and who have not had a vasectomy must agree to comply with highly effective methods of from the time of IMP administration until 4 months after the last dose of IMP.
  • Non-smoker, or mild smoker (no more than 10 cigarettes per day).
  • Have a between 18 and 30 kg/m2 inclusive and weigh at least 45 kg and no more than 100 kg inclusive.
  • Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating.
  • Provision of signed, written and dated informed consent for optional genetic/biomarker research.
  • Evidence of completion of an appropriate vaccination regimen to SARS-CoV-2 at least 14 days prior to screening as appropriate and recommended in contemporaneous local, regional, or national guidelines.

Part 1 (Healthy Subjects), Part 3a (Healthy Japanese Subjects) and Part 3b (Healthy Chinese Subjects):

  • Healthy male and female (of childbearing and non childbearing potential) subjects aged 18 to 50 years inclusive.

Part 1a (in case of dose escalation in patients) and Part 2 (Patients with Crohn's Disease):

  • Male and female (of childbearing and non childbearing potential) patients with Crohn's disease aged 18 to 60 years inclusive.
  • Patients with confirmed Crohn's disease (diagnosed via endoscopy, histology and/or imaging) with onset of symptoms at least 3 months prior to screening.
  • Active disease, defined by at least one symptom and sign consistent with Crohn's disease AND at least one of the following:

    1. CRP > 5mg/L at screening.
    2. Faecal calprotectin > 250μg/g at screening.
    3. Evidence of active inflammation on cross-sectional imaging within past 3 months prior to screening.
    4. Evidence of active inflammation on endoscopy within past 3 months prior to screening.

Part 3a (Japanese Subjects) • Subject is a native of Japan; defined as having both parents and 4 grandparents who are Japanese. This includes second and third generation subjects of Japanese descent whose parents or grandparents are living in a country other than Japan.

Part 3b (Chinese Subjects)

  • Healthy Chinese subjects. Subjects of Chinese ancestry are eligible based on meeting all of the following:

    1. Born in mainland China, Hong Kong, or Taiwan.
    2. Descendants of 4 ethnic Chinese grandparents and 2 ethnic Chinese parents.
    3. Have lived outside China for less than 10 years at the time of screening.

Exclusion criteria

Exclusion Criteria:

All Study Parts:

  • Any illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of Medicinal Product (IMP).
  • Any positive result on Screening for , anti-HBc antibody, anti- antibody, and .
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, or, history of hypersensitivity to drugs with a similar chemical structure or class to AZD7798.
  • For females of using hormonal : Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
  • Subjects with a positive diagnostic nucleic acid test (using PCR) for SARS-CoV-2 prior to dosing.
  • Live or attenuated vaccine within 4 weeks of Visit 1 and until the end of the follow up period.
  • An active infection, or history of serious infection within the preceding 28 days.
  • Use of antibiotics within 28 days prior to the first administration of IMP.
  • History of symptomatic herpes simplex (excluding cold sores) or herpes zoster infection within 3 months prior to screening.
  • Positive or indeterminate TB QuantiFERON test.
  • Has received another new chemical entity within 30 days/5 half-lives of the first administration of IMP in this study.
  • Subjects who cannot communicate reliably with the Investigator.
  • Vulnerable subjects.

Part 1 (Healthy Subjects), Part 3a (Japanese Subjects, and Part 3b (Chinese Subjects):

  • Any laboratory values with deviations.
  • Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results other than those described under exclusion criterion number 20, as judged by the Investigator.
  • Abnormal vital signs, after 5 minutes supine rest at screening and admission.
  • Known or suspected history of drug abuse in the last 1 year as judged by the Investigator.
  • History of alcohol abuse or excessive intake of alcohol within the last 1 year. as judged by the Investigator.
  • Positive screen for drugs of abuse at screening or admission to the Clinical Unit or positive screen for alcohol on admission to the Clinical Unit prior to the first administration of the IMP.
  • Excessive intake of caffeine containing drinks or food (eg, coffee, tea, chocolate,) as judged by the Investigator.

Part 1a (in case of dose escalation in patients) and Part 2 (Patients with Crohn's Disease):

  • Patients with any uncontrolled medical conditions, other than active Crohn's disease, that in the opinion of the Investigator put the patient at unacceptable risk or interfere with study assessments or integrity of the data.
  • Current diagnosis of ulcerative colitis, indeterminate colitis, inflammatory bowel disease-unclassified, infectious colitis, or ischaemic colitis.
  • History of CMV colitis 12 months prior to screening.
  • Patients with fulminant Crohn's disease or toxic megacolon.
  • Planned surgery for Crohn's disease prior to the end of study follow up visit.
  • Patients with symptomatic intestinal stenosis, known pre-stenotic dilatation, undrained fistula(e), or abscesses.
  • Initiation or change in dose of azathioprine or mercaptopurine (including initiation or discontinuation of allopurinol) within 4 weeks of the first administration of IMP.
  • Treatment with methotrexate, ciclosporin, tacrolimus or thalidomide within 4 weeks of the first administration of IMP.
  • Treatment with an anti-TNF biologic within 8 weeks of the first administration of IMP, unless therapeutic drug monitoring is performed and drug concentrations are undetectable.
  • Treatment with any biologic, other than an anti-TNF, within 12 weeks or with undetectable serum concentrations prior to the first administration of IMP, unless therapeutic drug monitoring is performed and drug concentrations are undetectable.
  • Treatment with rituximab within 12 months prior to the first administration of IMP.
  • Any laboratory values with deviations.
  • Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results other than those described under exclusion criterion number 49, as judged by the Investigator.
  • Abnormal vital signs, after 5 minutes supine rest, defined as any of the following at screening and admission.
  • Any clinically important abnormalities in rhythm, conduction, or morphology of the resting and any clinically important abnormalities in the 12 lead ECG.
  • Unstable lifestyle factors, such as alcohol use to excess or recreational drug use, to the extent that in the opinion of the Investigator they would interfere with the ability of a patient to complete the study.
  • Current or history of malignancy.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Part 1a - Cohort 1: AZD7798 dose 1

    A total of 6 subjects will receive single ascending doses of AZD7798.

    Biological: AZD7798

  • Experimental
    Part 1a - Cohort 2: AZD7798 dose 2

    A total of 6 subjects will receive single ascending doses of AZD7798.

    Biological: AZD7798

  • Experimental
    Part 1a - Cohort 3: AZD7798 dose 3

    A total of 6 subjects will receive single ascending doses of AZD7798.

    Biological: AZD7798

  • Experimental
    Part 1a - Cohort 4: AZD7798 dose 4

    A total of 6 subjects will receive single ascending doses of AZD7798.

    Biological: AZD7798

  • Experimental
    Part 1a - Cohort 5: AZD7798 dose 5

    A total of 6 subjects will receive single ascending doses of AZD7798.

    Biological: AZD7798

  • Experimental
    Part 1a - Cohort 6: AZD7798 dose 6

    A total of 6 subjects will receive single ascending doses of AZD7798.

    Biological: AZD7798

  • Experimental
    Part 1a - Cohort 7: AZD7798 dose 7

    A total of 6 subjects will receive single ascending doses of AZD7798.

    Biological: AZD7798

  • Experimental
    Part 1b - Cohort 8: AZD7798 dose 8

    A total of 6 subjects will receive repeat doses of AZD7798.

    Biological: AZD7798

  • Experimental
    Part 1a - Spare Cohort 9: AZD7798 dose 9

    A total of 6 subjects will receive a single ascending dose of AZD7798.

    Biological: AZD7798

  • Experimental
    Part 2 - Cohort 10: AZD7798 + AZD7798

    A total of 4 subjects will receive a single dose on Day 1 followed by a single dose on Day 15.

    Biological: AZD7798

  • Experimental
    Part 2 - Cohort 11: Placebo + AZD7798

    A total of 2 subjects will receive placebo on day 1 followed by AZD7798 on day 15.

    Biological: AZD7798

  • Experimental
    Part 2 - Cohort 12: AZD7798 + Placebo

    A total of 2 subjects will receive AZD7798 on day 1 followed by placebo on day 15.

    Biological: AZD7798

  • Experimental
    Placebo: Part 1a and Part 1b

    A total of 2 subjects per cohort will receive placebo.

    Biological: Placebo

  • Experimental
    Part 3a - Cohort 12: AZD7798

    A total of 6 subjects will receive single ascending doses of AZD7798.

    Biological: AZD7798

  • Experimental
    Part 3b - Cohort 13: AZD7798

    A total of 6 subjects will receive single ascending doses of AZD7798.

    Biological: AZD7798

  • Experimental
    Placebo: Part 3a and Part 3b

    A total of 2 subjects per cohort will receive placebo.

    Biological: Placebo

Interventions

  • BiologicalAZD7798

    Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

  • BiologicalPlacebo

    Subjects will receive placebo matching the AZD7798 dose as a single ascending dose or as a repeat dose.

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    The safety and tolerability of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Until follow-up (Day 85) or Early termination (ET)

Secondary outcomes

  1. Area under plasma concentration time curve from zero to infinity (AUCinf)

    The AUCinf of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  2. AUClast

    The AUClast of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  3. Maximum serum concentration (Cmax)

    The Cmax of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  4. Time to reach maximum serum concentration (tmax)

    The tmax of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  5. Time to last measurable concentration (tlast)

    The tlast of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  6. Terminal elimination half-life (t½λz)

    The t½λz of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  7. Systemic clearance (CL)

    The CL of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  8. Apparent total clearance (CL/F)

    The CL/F of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  9. Volume of distribution based on the terminal phase (Vz)

    The Vz of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  10. Apparent volume of distribution based on terminal phase (Vz/F)

    The Vz/F of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  11. Bioavailability (F)

    The F of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  12. Volume of distribution at steady state (Vss)

    The Vss of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  13. AUClast/D

    The AUClast/D of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  14. AUCinf/D

    The AUCinf/D of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  15. Cmax/D

    The Cmax/D of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

  16. Percentage of patients with antidrug antibodies (ADAs)

    The immunogenicity of AZD7798 following administration of single ascending doses will be assessed.

    Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85

07

Study locations

1 site
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Nov 2024, 28 months.

Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 28 months is above that.

Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2022
First posted
Jul 11, 2022
StartActual
Jul 12, 2022
Primary completionActual
Nov 14, 2024
CompletionActual
Nov 27, 2024
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05452304
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Jul 12, 2022
Primary completion
Nov 14, 2024
Completion
Nov 27, 2024
Last update
Dec 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD7798

Start the discussion